As the summer was ending,I sat down with Isaac Ro, Life Sciences Executive, who I originally met at the Blue Genes Bash several years ago. Isaac left Goldman Sachs for Thrive Early Detection, where Bert Vogelstein and the group were working on liquid biopsy. After Thrive was acquired by Exact Sciences, Isaac left and became CFO at Sema4, which was a company where I worked as well. After taking Sema4 public, Haystack oncology is his newest venture which works on MRD in cancer. We talk data, the financial climate in genetics, and what it's like to pivot to a management role where you're relying on everyone in the team for company success.
